* Download comes with a free subscription to our newsletter. You can unsubscribe any time. You will not get duplicate emails if you download more than one report.

  1. 1

British drug giant GlaxoSmithKline is investing $300 million in consumer genetics company 23andMe, forging a four-year collaboration to discover medicines using human genetics as a guide.

The partnership establishes GSK as 23andMe’s exclusive collaborator for drug target discovery, the companies said Wednesday. It comes with an option to extend for a fifth year, and funding and proceeds will be split equally.

The announcement comes as GSK embarks on a new research strategy under new Chief Scientific Officer Hal Barron, a drug industry veteran. The new approach focuses on the immune system, genetics and advanced analytics and technology.

  1. You must first login , or register before you can comment.

    Markdown formatting available